Femasys reported a substantial miss on top and bottom-line results for the second quarter 2026, with revenue declining nearly 19% year-over-year. The results highlight challenges in the commercial ramp-up of its fertility portfolio, although a subsequent $30 million private placement has significantly strengthened the company's liquidity position to fund ongoing clinical and commercial operations.
Key Highlights
- Revenue of $331,827 fell 18.9% year-over-year from $409,268, missing consensus estimates by approximately 80%.
- Net loss per share reached $1.33, compared to an expected loss of $0.10, reflecting increased clinical costs and higher weighted-average shares outstanding.
- Subsequent to the quarter's end, the company secured $30 million in gross proceeds through a private placement to fund the FemBloc clinical program and FemaSeed commercial strategy.